PRISM will be accepting submissions for our next screen July 8 – July 26!

DMSO-soluble small molecules (single agent and combination format), and single agent antibodies, ADCs, and growth-inhibiting cytokines will be accepted for our 930 cancer cell line screen.

Aqueous screening

In addition to the standard DMSO-based screening format, PRISM now has the ability to screen aqueous antibodies, antibody-drug conjugates, and growth-inhibiting cytokines. We are accepting test agents for our next screen January 16 – February 2, 2024. Contact our team for more information on how to submit. This new screening format has been made possible […]

Drug combination screening

We are accepting test agents for our next screen January 16 – February 2, 2024. Contact our team for more information on how to submit. Combination screening requires careful selection of drug doses which can be especially difficult in a pooled context. Therefore, it is only recommended to use this assay for test agents with […]

The PRISM assay workflow

Cell line barcoding and pool preparation The PRISM assay uses over 900 human cancer cell lines with deep multi-omic characterization. Cell lines were stably transfected with unique DNA barcodes and quality control tested prior to use in the PRISM assay to: Verify the absence of mycoplasma Verify cell line identity with SNP fingerprinting Confirm unique […]

Background and history

Profiling Relative Inhibition Simultaneously in Mixtures (PRISM) is a unique, novel technology that enables the rapid screening of thousands of drugs against over 900 human cancer cell line models using a high-throughput, multiplexed approach. PRISM was first conceptualized by researchers at the Broad Institute of MIT and Harvard in 2012 and scaled into a high-throughput […]